The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
NCT ID: NCT01317186
Last Updated: 2011-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)
NCT01552525
FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
NCT01703234
ADMA Levels in End-Stage Renal Disease
NCT00350974
Prevention of Acute Kidney Injury - Molecular Mechanisms of Dietary Pre-conditioning in Human
NCT02745444
Pentraxin-3 in Chronic Renal Failure
NCT01397773
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Stage 2 Non-diabetic Chronic Kidney Disease
No interventions assigned to this group
Group II
Stage 3 Non-diabetic Chronic Kidney Disease
No interventions assigned to this group
Group III
Stage 4 Non-diabetic Chronic Kidney Disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic kidney disease of stage 2-4
Exclusion Criteria
* taking vitamin d therapy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara Education and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ankara Education and Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara Education and Research Hospital
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEPH002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.